Is Eliquis publicly traded?

Eliquis itself is not publicly traded. It is a product co-owned by two publicly traded companies: Bristol-Myers Squibb (BMY) and Pfizer (PFE). Investors can gain exposure to Eliquis revenue by owning shares in either company.

When was Eliquis approved?

The FDA approved Eliquis on December 28, 2012, for stroke prevention in patients with nonvalvular atrial fibrillation. The European Medicines Agency approved it in May 2011 for prevention of venous thromboembolism after hip or knee replacement surgery.

When will generic Eliquis be available?

Generic apixaban is already available in some European markets following the May 2026 patent expiry. In the United States, generic entry is scheduled for April 1, 2028, under patent litigation settlements between BMS, Pfizer, and multiple generic manufacturers.

What is Eliquis used for?

Eliquis is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment and prevention of deep vein thrombosis and pulmonary embolism. It works by inhibiting factor Xa, an enzyme in the blood coagulation cascade.

Healthcare & Pharmaceuticals

Who Owns Eliquis?

Q: Who owns Eliquis?

Eliquis is co-owned by Bristol-Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE). BMS discovered the drug and the two companies share development costs and profits equally under a worldwide collaboration agreement signed in 2007.

Eliquis (apixaban) is co-owned by Bristol-Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE) under a worldwide collaboration agreement signed in 2007. BMS discovered the drug and the two companies share development costs and profits equally on a global basis. Eliquis generated $14.4 billion in worldwide revenue in 2025, making it one of the best-selling pharmaceutical products of all time. US generic entry is set for April 2028 under patent litigation settlements.

Parent Company

Pfizer Inc.

Founded

2012

Status

Publicly Traded

Headquarters

New York, New York, USA

Eliquis Timeline

1849

Pfizer Inc.

Parent company established in New York, New York, USA

Company Founded

2012

Eliquis

Founded by Bristol-Myers Squibb (discovery), Pfizer (co-development)

Founded

mid rangemarket leaderGlobalall-agesOfficial Website

Who Owns Eliquis?

Parent Company: Pfizer Inc.
Ownership Type: Co owned
Company Type: Publicly Traded
Stock Ticker: NYSE: PFE

Brand	Parent Company	Ownership Type
Eliquis	Pfizer Inc.	Co owned

History of Eliquis

Founded: 2012
Founders: Bristol-Myers Squibb (discovery), Pfizer (co-development)

Apixaban was discovered by researchers at Bristol-Myers Squibb. The compound is a small molecule that selectively inhibits factor Xa, an enzyme in the coagulation cascade that plays a central role in blood clot formation. By blocking factor Xa, apixaban reduces the production of thrombin, the enzyme that converts fibrinogen to fibrin, thereby preventing clot formation.

BMS and Pfizer announced their worldwide collaboration on apixaban on April 26, 2007. The agreement covered development and commercialization across a broad range of venous and arterial thrombotic conditions. At the time, apixaban was in Phase III clinical trials. The European Medicines Agency approved Eliquis in May 2011 for prevention of venous thromboembolism after elective hip or knee replacement surgery. The FDA approved Eliquis on December 28, 2012, for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Subsequent FDA approvals expanded Eliquis's indications. In 2014, the FDA approved Eliquis for the prophylaxis of deep vein thrombosis and pulmonary embolism in patients who have undergone hip or knee replacement surgery. Later that year, the agency approved Eliquis for the treatment of DVT and PE, and for reducing the risk of recurrence of DVT and PE following initial therapy.

The ARISTOTLE trial, published in the New England Journal of Medicine in 2011, was the pivotal study that demonstrated Eliquis's superiority over warfarin. The trial enrolled over 18,000 patients with atrial fibrillation and showed that apixaban reduced the risk of stroke or systemic embolism by 21 percent compared to warfarin, while also causing significantly less major bleeding and lowering overall mortality. These results established Eliquis as a preferred oral anticoagulant and drove rapid adoption.

By the mid-2010s, Eliquis had become the market-leading oral anticoagulant in the United States and globally. Sales grew from approximately $774 million in 2015 to over $10 billion by 2022. In 2025, worldwide Eliquis revenue reached $14.4 billion, with BMS reporting $10.2 billion in U.S. sales and $4.2 billion internationally, and Pfizer reporting approximately $7.96 billion in combined alliance and product revenues.

In 2026, Eliquis continued to grow despite the implementation of Medicare price negotiation under the Inflation Reduction Act. A Medicare maximum fair price of $231 per 30-day supply took effect on January 1, 2026. BMS and Pfizer also began selling Eliquis directly to cash-paying U.S. patients at a discount of more than 40 percent, and reduced the list price for commercial patients. In the second quarter of 2026, BMS reported Eliquis sales of $4.48 billion, up 22 percent year over year, driven by growth in demand. BMS raised its full-year 2026 Eliquis revenue growth guidance to 20 to 25 percent, up from its previous forecast of 10 to 15 percent.

About Pfizer Inc.

What does Pfizer own?
Pfizer owns a portfolio of prescription medicines and vaccines spanning oncology, cardiovascular, immunology, vaccines, and rare diseases. Key products include Eliquis (anticoagulant), Prevnar (pneumococcal vaccine), Ibrance (breast cancer), Vyndaqel (rare heart disease), Paxlovid (COVID-19 antiviral), Comirnaty (COVID-19 vaccine, with BioNTech), and Abrysvo (RSV vaccine). The 2023 acquisition of Seagen added oncology antibody-drug conjugates including Padcev, Adcetris, and Tukysa. The 2025 acquisition of Metsera added obesity treatment candidates to the pipeline.

Is Pfizer publicly traded?
Yes, Pfizer Inc. is listed on the New York Stock Exchange under ticker PFE. The company has been publicly traded since 1944. Pfizer has no single controlling shareholder, with major institutional holders including Vanguard Group, BlackRock, and State Street. Pfizer is a component of the Dow Jones Industrial Average and the S&P 500.

Who founded Pfizer?
Pfizer was founded in 1849 in Brooklyn, New York by Charles Pfizer and his cousin Charles Erhart. Charles Pfizer was a German-born chemist who emigrated to the United States. The company's first product was santonin, an antiparasitic agent. Pfizer's breakthrough into modern pharmaceuticals came during World War II when the company developed large-scale penicillin production using deep-tank fermentation.

Where is Pfizer headquartered?
Pfizer is headquartered in New York City, New York, USA. The company maintains its principal executive offices in Midtown Manhattan. Pfizer operates manufacturing facilities in the United States, Belgium, Ireland, the United Kingdom, Germany, Japan, China, India, and Brazil, and sells products in more than 125 countries worldwide.

How many products does Pfizer sell?
Pfizer sells dozens of prescription medicines and vaccines across multiple therapeutic areas. The company's portfolio includes products in oncology, vaccines, cardiovascular, immunology, rare diseases, and hospital products. Several of Pfizer's products each generate over $1 billion in annual revenue, including Eliquis, Prevnar, Ibrance, and Vyndaqel. The company's research pipeline includes hundreds of compounds in various stages of clinical development.

Who owns Pfizer?
Pfizer Inc. is publicly traded on the NYSE with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. Major institutional shareholders include Vanguard Group, BlackRock, and State Street. Albert Bourla serves as Chairman and CEO. Pfizer has no founding family or private equity controlling shareholder.

What is Pfizer's financial performance?
For full-year 2025, Pfizer reported revenue of $62.6 billion, a 2% decrease from $63.6 billion in FY2024. Excluding COVID-19 products (Comirnaty and Paxlovid), revenue grew 6% operationally. Net income was $7.77 billion, down 3% from $8.03 billion. Adjusted diluted EPS was $3.22, up 4% from $3.11. Net cash from operations was $11.7 billion. For FY2026, Pfizer projects revenue of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00.

Founded: 1849
Headquarters: New York, New York, USA
Company Type: Publicly Traded
Stock: NYSE: PFE
Revenue: $62.6 billion (FY2025)
Employees: approximately 88,000

Visit Pfizer Inc. website

View full company profile for Pfizer Inc.

Where Is Eliquis Made / Based?

Headquarters: New York, New York, USA
Manufacturing / Operations: United States, Belgium, Ireland

Eliquis Categories & Tags

Cardiovascular Anticoagulant Blood Thinner Atrial Fibrillation Stroke Prevention Apixaban

Eliquis Recalls & Controversies

Eliquis has maintained a strong safety profile since its FDA approval in 2012, but the drug has been the subject of several notable controversies and legal proceedings.

Patent Litigation: BMS and Pfizer have actively enforced the Eliquis patent estate through Hatch-Waxman litigation against multiple generic manufacturers seeking to market apixaban in the United States. In September 2024, the companies sued Indian generic manufacturer Umedica Laboratories in the District of Delaware over patent US9326945B2. The case was voluntarily dismissed without prejudice after 15 days. Settlements with other generic manufacturers established the April 2028 U.S. generic entry date.

Medicare Price Negotiation: Eliquis was among the first 10 drugs selected for Medicare price negotiation under the Inflation Reduction Act. The negotiated maximum fair price of $231 per 30-day supply took effect on January 1, 2026. BMS and Pfizer have criticized the negotiation process, arguing that the reduced price could impact revenue ahead of the 2028 patent cliff. However, BMS raised its 2026 Eliquis revenue guidance after stronger-than-expected demand in the first half of the year.

Bleeding Risk: Like all anticoagulants, Eliquis carries a risk of bleeding, including life-threatening hemorrhage. The drug carries an FDA boxed warning advising against premature discontinuation and noting that spinal and epidural hematomas can occur in patients receiving neuraxial anesthesia. These risks are well-characterized and reflected in the prescribing information.

Pricing and Access: Eliquis has faced criticism over its high cost, particularly in the United States where the list price has been significantly higher than in other countries. The Medicare price negotiation and the companies' voluntary cash-price discount program represent responses to these concerns.

Eliquis Ownership: Pros & Cons

Advantages

+Market-leading oral anticoagulant with proven superiority over warfarin
+$14.4 billion in 2025 revenue provides substantial cash flow for both companies
+Backed by the ARISTOTLE trial, one of the largest cardiovascular studies ever conducted
+WHO Essential Medicines List inclusion supports global adoption
+Co-development spreads financial risk between two major pharmaceutical companies
+Strong clinical adoption with established prescriber base

Considerations

-European patent expiry in May 2026 has begun triggering generic competition
-U.S. generic entry set for April 2028 will cause major revenue erosion
-Revenue projected to fall from $14.4 billion (2025) to under $1 billion by 2031
-Medicare price negotiation reduced net revenues starting January 2026
-Heavy revenue concentration creates risk for BMS, which relies on Eliquis for 30 percent of total revenue
-Bleeding risk inherent to all anticoagulants requires careful patient management

Frequently Asked Questions About Eliquis

Sources & Further Reading

Where to Buy

Disclosure: We may earn commission from purchases

Eliquis on Amazon

Competitors to Eliquis

These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.

Brand	Parent Company	Country	Founded	Market Position	Primary Market	Gender Target
Lovenox	Sanofi	France	1993	Mass market	Global	All Genders

Learn More About Competitors

Healthcare Pharmaceuticals

Lovenox

Owned by Sanofi

Sanofi anticoagulant brand (enoxaparin sodium), FDA approved in 1993 for preventing and treating blood clots including DVT and pulmonary embolism.

cardiovascularenoxaparinanticoagulant

Competitive Analysis

Market Positioning: Eliquis competes with 1 brands in the same categories, ranging from mass market to luxury positioning.

Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.

Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.

Independent Alternatives to Eliquis

Looking for brands with different ownership structures? These similar brands are not owned by Pfizer Inc., giving you alternative choices that support different corporate structures.

Healthcare Pharmaceuticals

Pharmacy Direct

Owned by Chempro Chemists

Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.

online-pharmacymail-orderdigital-health

Privately Owned

Pharmacy Direct is privately owned, unlike Eliquis which is under a publicly traded parent company.

Healthcare Pharmaceuticals

Tirosint

Owned by IBSA Institut Biochimique S.A.

IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.

levothyroxinehypothyroidismthyroid

Privately Owned

Tirosint is privately owned, unlike Eliquis which is under a publicly traded parent company.

Healthcare Pharmaceuticals

Novo Nordisk

Owned by Novo Nordisk

Danish pharmaceutical company specializing in diabetes care and obesity treatment. Founded in 1923, headquartered in Bagsvaerd, Denmark. World leader in diabetes care and a leader in obesity treatment with Ozempic, Wegovy, and the investigational CagriSema. CEO Lars Fruergaard Jorgensen departed in March 2025; interim leadership under board chairman Helge Lund until a permanent CEO is appointed.

pharmaceuticalsdiabetesobesity

Publicly Traded

Novo Nordisk operates independently without a large parent corporation.

Healthcare Pharmaceuticals

Alcon

Owned by Alcon Inc.

Independent publicly traded global eye care company headquartered in Geneva, Switzerland, specializing in surgical equipment, contact lenses, and ophthalmic products. Spun off from Novartis in April 2019.

eye-carecontact-lensesophthalmic

Publicly Traded

Alcon operates independently without a large parent corporation.

Healthcare Pharmaceuticals

GE HealthCare

Owned by GE HealthCare Technologies Inc.

Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.

healthcare-technologymedical-imagingdiagnostics

Publicly Traded

GE HealthCare operates independently without a large parent corporation.

Healthcare Pharmaceuticals

GoodRx

Owned by GoodRx Holdings, Inc.

American healthcare technology platform providing prescription drug price comparison, discount coupons, and telehealth services to help consumers find affordable healthcare options.

prescription-savingshealthcare-technologydrug-prices

Publicly Traded

GoodRx operates independently without a large parent corporation.

Pfizer Inc. Stock Information

Jobs at Pfizer Inc.

Latest News About Eliquis

People Also Searched

Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Branddermatology

Accutane

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Brand in Healthcare & Pharmaceuticals

acne-treatmentprescription

Brandpharmaceutical

Activase

Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.

Brand in Healthcare & Pharmaceuticals

thrombolyticstroke-treatment

Brandcontact-lenses

Acuvue

Acuvue is the world's leading contact lens brand, owned by Johnson & Johnson Vision Care, a division of Johnson & Johnson. The brand covers daily, weekly, and monthly disposable soft contact lenses sold in more than 100 countries.

Brand in Healthcare & Pharmaceuticals

vision-carejohnson-and-johnson

Browse All Healthcare & Pharmaceuticals

Healthcare & Pharmaceuticals

Who Owns Eliquis?

Parent Company

Pfizer Inc.

Founded

2012

Status

Publicly Traded

Headquarters

New York, New York, USA